选择性COX-2抑制剂和非选择性COX-1和COX-2抑制剂在预防全髋关节置换术后异位骨化的Meta分析
摘要点击次数: 1929   全文下载次数: 1077   投稿时间:2013-08-20    
作者Author单位AddressE-Mail
徐步国 XU Bu-guo 浙江大学医学院附属第二医院骨科, 浙江 杭州 310009
苍南县第三人民医院骨科, 浙江 温州 325804
Department of Orthopaedics, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang, China  
薛德挺 XUE De-ting 浙江大学医学院附属第二医院骨科, 浙江 杭州 310009 Department of Orthopaedics, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang, China  
王祥华 WANG Xiang-hua 浙江大学医学院附属第二医院骨科, 浙江 杭州 310009 Department of Orthopaedics, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang, China  
严世贵 YAN Shi-gui 浙江大学医学院附属第二医院骨科, 浙江 杭州 310009 Department of Orthopaedics, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, Zhejiang, China zrjwsj@zju.edu.cn 
期刊信息:《中国骨伤》2014年,第27卷,第7期,第609-614页
DOI:10.3969/j.issn.1003-0034.2014.07.018
基金项目:
中文摘要:

目的:比较选择性环加氧酶-2(COX-2)抑制剂和传统的非选择性NSAIDs药用于预防全髋关节置换(THA)术后异位骨化(HO)临床疗效。

方法:通过计算机检索MEDLINE、EMBASE、CENTRAL、科学引文索引等数据库,收集选择性COX-2抑制剂和非选择性COX-1和COX-2抑制剂用于预防全髋关节置换术后异位骨化的随机临床试验。按照Cochrane协作网的标准对纳入的文献进行质量评估并提取有效数据,应用统计软件Stata10.0版本进行数据分析。比较两组在不同Brooker分期的异位骨化发生率。

结果:共纳入4个符合条件的随机对照试验,808例患者。Meta分析结果表明,两组间异位骨化总发病率比较差异无统计学意义(RR=1.08,95%CI:0.71~1.64,P=0.73),重度异位骨化发病率(BrookerⅡ,Ⅲ)(RR=0.83,95%CI:0.48~1.42,P=0.49)和任意Brooker分型的HO,两组之间比较差异无统计学意义。在整个研究中,16例接受非选择性COX抑制剂的患者(4.4%)因胃肠道反应终止治疗;而选择性COX-2抑制剂组中10例患者(2.7%)因胃肠道反应终止治疗。

结论:选择性COX-2抑制剂与非选择性NSAIDs药用于预防全髋关节置换术后异位骨化同样有效。考虑到非选择性NSAIDs药的胃肠道不良反应,建议选择性COX-2抑制剂的预防全髋关节置换术后异位骨化。
【关键词】骨化,异位性  关节成形术,置换,髋  消炎药,非甾类  Meta分析
 
Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty:a meta-analysis of randomised trials
ABSTRACT  

Objective: To evaluate the clinical efficiency of selective cyclo-oxygenase-2 (COX-2) inhibitor compared to traditional nonselective NSAIDs for the prevention of heterotopic ossification (HO) after total hip arthroplasty (THA).

Methods: By searching Medline,Embase,CENTRAL(Cochrane Central Register of Controlled Trials) and Science Citation Index et al,only randomised controlled studies of selective COX-2 inhibitors VS nonselective COX-1 and COX-2 inhibitors for the prevention of HO after THA were included. The quality assessment of included studies was evaluated according to the standard of the Cochrane Collaboration,and the data were analysised by statistic software Stata 10.0. The HO incidence of both groups in different degrees was compared.

Results: Four eligible randomised controlled trials of totally 808 patients were included. Meta-analysis results showed that no statistically significant difference was found in overall incidence of HO (RR=1.08,95%CI:0.71-1.64,P=0.73),incidence of moderate severe HO (BrookerⅡand Ⅲ)(RR=0.83,95% CI:0.48-1.42,P=0.49) and any grade of Brooker classification between two groups. In all included studies,16 patients receiving nonselective COX inhibitor (4.4%) discontinued treatment because of gastrointestinal toxicity,whereas 10 patients in the selective COX-2 inhibitor group (2.7%) discontinued for gastrointestinal side effects.

Conclusion: The selective COX-2 inhibitors are as equally effective as nonselective NSAIDs for the prevention of HO after THA. Considering the side effects of nonselective NSAIDs,selective COX-2 inhibitors were recommend for the prevention of HO after THA.
KEY WORDS  Ossification,heterotopic  Arthroplasty,replacement,hip  Anti-inflammatory agents,non-steroidal  Meta-analysis
 
引用本文,请按以下格式著录参考文献:
中文格式:徐步国,薛德挺,王祥华,严世贵.选择性COX-2抑制剂和非选择性COX-1和COX-2抑制剂在预防全髋关节置换术后异位骨化的Meta分析[J].中国骨伤,2014,27(7):609~614
英文格式:XU Bu-guo,XUE De-ting,WANG Xiang-hua,YAN Shi-gui.Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty:a meta-analysis of randomised trials[J].zhongguo gu shang / China J Orthop Trauma ,2014,27(7):609~614
阅读全文  下载  查看/发表评论  下载PDF阅读器
关闭




版权所有:《中国骨伤》杂志社京ICP备12048066号-2  版权声明
地址:北京市东直门内南小街甲16号,100700
电话:010-64089487 传真:010-64089792 Email:zggszz@sina.com

京公网安备 11010102004237号